Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!

Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.

wallstreetcn20:47 ET

Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications

Benzinga15:50 ET

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst

Benzinga15:27 ET

AbbVie's Options Frenzy: What You Need to Know

Benzinga15:01 ET

A Look Into Abbott Laboratories Inc's Price Over Earnings

Benzinga14:00 ET

9 Health Care Stocks Whale Activity In Today's Session

Benzinga13:35 ET